Navigation Links
New Treatment Rivals Chemotherapy For Lymphoma, Study Finds

icular non-Hodgkin's lymphoma after other treatments have failed. The newly published research involves Bexxar as a first-line treatment for this disease.

Non-Hodgkin's lymphoma, the nation's sixth leading cause of cancer death, is a cancer of the lymph system, which is part of the immune system. Lymphoma spreads easily through the lymph system and the bloodstream and consequently tends to be widespread when it is diagnosed. Traditional treatment often involves intensive chemotherapy, or a combination of chemotherapy and the monoclonal antibody rituximab. These treatments are usually given every three weeks over a span of up to six months and can cause many unpleasant side effects, including nausea, hair loss and infections.

Follicular lymphoma is the second most common type of non-Hodgkin's lymphoma and is not considered to be curable using these traditional treatments; even after patients initially have a response to treatment, the disease almost always comes back and becomes more difficult to treat.

Bexxar, whose chemical name is tositumomab and iodine I 131 tositumomab, combines an antibody that seeks out cancer cells, and a radioactive form of the element iodine. When injected, it travels like a guided missile through the bloodstream to bind to a protein found on the surface of the cancerous cells. The radiation zaps these malignant cells with minimal exposure to normal tissues.

With the Bexxar therapeutic regimen, a patient receives an injected test dose of radioactive Bexxar to determine how that patient's body processes the tagged antibody. Nuclear medicine scans are used to assess how quickly Bexxar reaches the tumor and how quickly the radiation disappears from the patient's body. One to two weeks after that initial dose, the patient then receives a custom-tailored therapeutic dose, and therapy is considered complete. The most common side effect is a temporary lowering of blood counts several weeks after the treatment. There
'"/>

Source:University Of Michigan Health System


Page: 1 2 3

Related biology news :

1. Discovery Could Lead To Novel Approaches In HIV Treatment
2. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
3. Effective Cancer Treatments Follow The Clock
4. Protein Discovery Could Unlock The Secret To Better TB Treatment
5. Natural Killers Could Lead to New Hepatitis Treatments
6. FDA Approves New Treatment for Chronic Hepatitis B
7. Study Finds Moderate Hypothermia A Safe Treatment For Traumatic Brain Injury In Kids
8. Drug Offers Alternative to Surgical Treatment After Miscarriage
9. Treatments have same target, different responses for lung cancer patients with genetic mutation
10. Minimally Invasive Cancer Treatments Highlighted
11. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Treatment Rivals Chemotherapy For Lymphoma Study Finds

(Date:7/23/2015)... July 23, 2015 Research and Markets ... the "Global Outlook of the Biometrics Industry ... The global biometrics market is likely ... commercial applications owing to the uptake of multiple ... transformation that enhances the growth of biometrics in ...
(Date:7/13/2015)... , July 13, 2015 Synaptics ... of human interface solutions, today announced sampling of ... and display driver integration (TDDI) product targeting smartphones ... first to combine Synaptics , best-in-class touch ... display driver technology developed in the company,s Japan ...
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, ... ), the leading developer of human interface ... authentication technology, the industry,s first fully hardware ... innovative Match-in-Sensor secure authentication technology is literally ... pattern storage and biometric matching within the ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... A new approach to mapping how proteins interact with ... Studies, could aid in the design of new drugs ... proteins using artificial amino acids, the Salk scientists determine ... its ligand, the molecule that turns it on. The ...
... leaf fragment collected decades ago on a Virginia canal bank ... plants, a 115- to 125-million-year-old species new to science. The ... a new question in the study of plant evolution: did ... distinctive pollen? Or did pollen come later? The find ...
... 2013 The American Association for the Advancement of Science ... Programme at EMBO, to its 2013 class of fellows. Election ... members by their peers and acknowledges contributions that help to ... by AAAS for her work looking at the societal impact ...
Cached Biology News:Salk scientists crack riddle of important drug target 2Salk scientists crack riddle of important drug target 3Evolution, Civil War history entwine in plant fossil with a tragic past 2Evolution, Civil War history entwine in plant fossil with a tragic past 3
(Date:7/29/2015)... Ala., July 29, 2015  HealthSouth ... nation,s largest providers of post-acute healthcare services, offering ... its results of operations for the second quarter ... quarter was characterized by strong volume growth in ... Adjusted EBITDA," said Jay Grinney, President and Chief ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... announces the launch of their 2nd generation cell therapy POD® design. The 2nd ... but it also represents a new POD® design. , “G-CON first offered ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... today announced its GHS Label Guide . To align chemical container labeling ... this guide includes explanations of label components, an example of an accurate label, ...
(Date:7/29/2015)...  Therapath Neuropathology ( www.Therapath.com ), a leader ... and Military Medical centers both domestically and worldwide.  ... Sweat Gland Nerve Fiber Density (SGNFD) for the ... Demonstration of a reduction in ... skin biopsy is a highly sensitive and specific ...
Breaking Biology Technology:HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27HealthSouth Reports Results for Second Quarter 2015 28HealthSouth Reports Results for Second Quarter 2015 29HealthSouth Reports Results for Second Quarter 2015 30HealthSouth Reports Results for Second Quarter 2015 31HealthSouth Reports Results for Second Quarter 2015 32HealthSouth Reports Results for Second Quarter 2015 33HealthSouth Reports Results for Second Quarter 2015 34HealthSouth Reports Results for Second Quarter 2015 35HealthSouth Reports Results for Second Quarter 2015 36
... BEIJING, Nov. 4, 2011 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. ... leading plasma-based biopharmaceutical companies in China, today announced that it ... 2011 financial results on Tuesday, November 8, 2011 at 8:00 ... China on the same day. Hosting the call ...
... Major milestone achieved in the commercial launch of ... ascites due to liver cirrhosis. Sequana Medical, ... (AKH Wien) reported that the first two commercial implants ... General Hospital in October, under the supervision of Univ. ...
... Nov. 3, 2011 Cumberland Pharmaceuticals Inc. (NASDAQ: ... hospital acute care and gastroenterology markets, today announced third quarter ... the three months ended September 30, 2011, net revenue was ... period. The growth in net revenue was driven by an ...
Cached Biology Technology:China Biologic to Host Earnings Conference Call on November 8, 2011 at 8:00 a.m. EST (NY) 2The Medical University of Vienna and Vienna General Hospital Perform the First two Commercial Implants Worldwide of Sequana Medical's ALFApump® System 2Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 2Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 3Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 4Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 5Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 6Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 7Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 8Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 9Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 10Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 11Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 12